D.E. Shaw & Co
NPCE icon

D.E. Shaw & Co’s Neuropace NPCE Stock Holding History

D.E. Shaw & Co’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$574K Buy
+43,625
New +$654K ﹤0.01% 3781

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co's NPCE Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in Neuropace (NPCE) in Q1 2026: 43,625 shares worth $574K. The stake represents ﹤0.01% of the portfolio and ranks #3781 among its holdings.

113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • D.E. Shaw & Co held 43,625 shares of Neuropace worth $574K as of Q1 2026.
  • Neuropace was a new D.E. Shaw & Co position in Q1 2026.
  • Neuropace made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3781 holding.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.